Neurologia最新文献

英文中文

Alemtuzumab and autoimmune polyglandular syndrome with type 1 diabetes mellitus. 阿仑妥珠单抗与伴有1型糖尿病的自身免疫性多腺综合征。

Neurologia

Pub Date : 2024-02-20 DOI: 10.1016/j.nrleng.2024.02.006

D A García Estévez, I Pinal Osorio, A Pato Pato

引用次数: 0

Opsoclonus-myoclonus syndrome and prostate cancer. An entity to be aware of. 肌阵挛综合征与前列腺癌。一个值得注意的实体。

Neurologia

Pub Date : 2024-02-20 DOI: 10.1016/j.nrleng.2024.02.004

C Guijarro-Castro, L Estallo-Guijarro

引用次数: 0

Mutations in the type IV collagen gen (COL4A1) as an unusual etiology of cerebrovascular disease in young adults. IV型胶原基因（COL4A1）突变是青壮年脑血管疾病的不寻常病因。

Neurologia

Pub Date : 2024-02-20 DOI: 10.1016/j.nrleng.2024.02.001

J Martín Prieto, E García-Serrano Fuertes, J Iglesias Bermejillo, A Luna Rodríguez

引用次数: 0

Serotonin syndrome induced by amoxicillin–clavulanic acid 阿莫西林克拉维酸诱发的血清素综合征。

Neurologia

Pub Date : 2024-02-20 DOI: 10.1016/j.nrleng.2024.02.003

L. Naya Ríos , D. Santos García , C. Cores Bartalomé , I. Docampo Carro

引用次数: 0

Sleep disorders in children with epilepsy 癫痫儿童的睡眠障碍。

Neurologia

Pub Date : 2024-02-01 DOI: 10.1016/j.nrleng.2024.01.011

M. Furones García, J.J. García Peñas, E. González Alguacil, T. Moreno Cantero, M.L. Ruiz Falcó, V. Cantarín Extremera, V. Soto Insuga

Introduction

Children with epilepsy present greater prevalence of sleep disorders than the general population. Their diagnosis is essential, since epilepsy and sleep disorders have a bidirectional relationship.

Objective

Determine the incidence of sleep disorders and poor sleep habits in children with epilepsy.

Methods

We conducted a cross-sectional study of patients under 18 years of age with epilepsy, assessing sleep disorders using the Spanish-language version of the Sleep Disturbance Scale for Children (SDSC), and sleep habits using an original questionnaire.

Results

The sample included 153 patients. Eighty-four percent of our sample presented some type of sleep alteration. The most frequent alterations were sleep-wake transition disorders (53%), sleep initiation and maintenance disorders (47.7%), and daytime sleepiness (44.4%). In 70% of cases, the patients’ parents reported that their child “slept well,” although sleep disorders were detected in up to 75.7% of these patients. Many patients had poor sleep habits, such as using electronic devices in bed (16.3%), requiring the presence of a family member to fall asleep (39%), or co-sleeping or sharing a room (23.5% and 30.5%, respectively). Those with generalised epilepsy, refractory epilepsy, nocturnal seizures, and intellectual disability were more likely to present sleep disorders. In contrast, poor sleep habits were frequent regardless of seizure characteristics.

Conclusions

Sleep disorders and poor sleep habits are common in children with epilepsy. Their treatment can lead to an improvement in the quality of life of the patient and his/her family, as well as an improvement in the prognosis of epilepsy.

导言：儿童癫痫患者的睡眠障碍发病率高于普通人群。对他们进行诊断至关重要，因为癫痫和睡眠障碍有双向关系：确定癫痫儿童睡眠障碍和不良睡眠习惯的发生率：我们对 18 岁以下的癫痫患者进行了横断面研究，使用西班牙语版儿童睡眠障碍量表（SDSC）评估睡眠障碍，并使用原始问卷评估睡眠习惯：样本包括 153 名患者。结果：样本包括 153 名患者，其中 84% 的患者出现了某种类型的睡眠改变。最常见的改变是睡眠-觉醒转换障碍（53%）、睡眠启动和维持障碍（47.7%）以及白天嗜睡（44.4%）。在 70% 的病例中，患者的父母称他们的孩子 "睡得很好"，但在这些患者中，有高达 75.7% 的人被发现有睡眠障碍。许多患者有不良的睡眠习惯，如在床上使用电子设备（16.3%）、需要家人陪伴才能入睡（39%）、同床共枕或共用一个房间（分别为 23.5% 和 30.5%）。患有全身性癫痫、难治性癫痫、夜间癫痫发作和智力障碍的患者更有可能出现睡眠障碍。相比之下，无论发作特征如何，不良睡眠习惯都很常见：结论：睡眠障碍和不良睡眠习惯在癫痫患儿中很常见。结论：睡眠障碍和不良睡眠习惯在儿童癫痫患者中很常见，对其进行治疗可提高患者及其家人的生活质量，并改善癫痫的预后。

{"title":"Sleep disorders in children with epilepsy","authors":"M. Furones García, J.J. García Peñas, E. González Alguacil, T. Moreno Cantero, M.L. Ruiz Falcó, V. Cantarín Extremera, V. Soto Insuga","doi":"10.1016/j.nrleng.2024.01.011","DOIUrl":"10.1016/j.nrleng.2024.01.011","url":null,"abstract":"<div><h3>Introduction</h3><p>Children with epilepsy present greater prevalence of sleep disorders than the general population. Their diagnosis is essential, since epilepsy and sleep disorders have a bidirectional relationship.</p></div><div><h3>Objective</h3><p>Determine the incidence of sleep disorders and poor sleep habits in children with epilepsy.</p></div><div><h3>Methods</h3><p>We conducted a cross-sectional study of patients under 18 years of age with epilepsy, assessing sleep disorders using the Spanish-language version of the Sleep Disturbance Scale for Children (SDSC), and sleep habits using an original questionnaire.</p></div><div><h3>Results</h3><p>The sample included 153 patients. Eighty-four percent of our sample presented some type of sleep alteration. The most frequent alterations were sleep-wake transition disorders (53%), sleep initiation and maintenance disorders (47.7%), and daytime sleepiness (44.4%). In 70% of cases, the patients’ parents reported that their child “slept well,” although sleep disorders were detected in up to 75.7% of these patients. Many patients had poor sleep habits, such as using electronic devices in bed (16.3%), requiring the presence of a family member to fall asleep (39%), or co-sleeping or sharing a room (23.5% and 30.5%, respectively). Those with generalised epilepsy, refractory epilepsy, nocturnal seizures, and intellectual disability were more likely to present sleep disorders. In contrast, poor sleep habits were frequent regardless of seizure characteristics.</p></div><div><h3>Conclusions</h3><p>Sleep disorders and poor sleep habits are common in children with epilepsy. Their treatment can lead to an improvement in the quality of life of the patient and his/her family, as well as an improvement in the prognosis of epilepsy.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 3","pages":"Pages 219-225"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000282/pdfft?md5=409885945c3981b75c43ed4b98751504&pid=1-s2.0-S2173580824000282-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139673992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The association between periodontitis and cerebrovascular disease, and dementia. Scientific report of the working group of the Spanish Society of Periodontology and the Spanish Society of Neurology 牙周炎与脑血管疾病和痴呆症之间的关系西班牙牙周病学协会 (SEPA) 和西班牙神经病学协会 (SEN) 工作组的科学报告。

Neurologia

Pub Date : 2024-01-13 DOI: 10.1016/j.nrleng.2024.01.002

Y. Leira , J. Vivancos , P. Diz , Á. Martín , M. Carasol , A. Frank

Objective

This article reviews the scientific evidence on the relationship between periodontitis and neurological disease, and particularly cerebrovascular disease and dementia. We also issue a series of recommendations regarding the prevention and management of periodontitis and these neurological diseases at dental clinics and neurology units.

Development

In response to a series of questions proposed by the SEPA-SEN working group, a literature search was performed, with no restrictions on study design, to identify the most relevant articles on the association between periodontitis and cerebrovascular disease and dementia from the perspectives of epidemiology, treatment, and the biological mechanisms involved in these associations.

Conclusions

Periodontitis increases the risk of ischaemic stroke and Alzheimer dementia. Recurrent bacterial infections and increased low-grade systemic inflammation seem to be possible biological mechanisms underlying this association. Limited evidence suggests that various oral health interventions can reduce the future risk of cerebrovascular disease and dementia.

目的：本文回顾了牙周炎与神经系统疾病，尤其是脑血管疾病和痴呆症之间关系的科学证据。我们还就牙科诊所和神经内科对牙周炎和这些神经系统疾病的预防和管理提出了一系列建议：针对SEPA-SEN工作组提出的一系列问题，我们进行了文献检索，不限制研究设计，从流行病学、治疗以及这些关联所涉及的生物机制等角度，找出牙周炎与脑血管疾病和痴呆症之间关联的最相关文章：结论：牙周炎会增加缺血性中风和老年痴呆症的风险。结论：牙周炎会增加缺血性中风和阿尔茨海默氏症痴呆症的风险，反复细菌感染和低度全身炎症的增加似乎是这种关联的可能生物机制。有限的证据表明，各种口腔健康干预措施可以降低未来罹患脑血管疾病和痴呆症的风险。

{"title":"The association between periodontitis and cerebrovascular disease, and dementia. Scientific report of the working group of the Spanish Society of Periodontology and the Spanish Society of Neurology","authors":"Y. Leira , J. Vivancos , P. Diz , Á. Martín , M. Carasol , A. Frank","doi":"10.1016/j.nrleng.2024.01.002","DOIUrl":"10.1016/j.nrleng.2024.01.002","url":null,"abstract":"<div><h3>Objective</h3><p>This article reviews the scientific evidence on the relationship between periodontitis and neurological disease, and particularly cerebrovascular disease and dementia. We also issue a series of recommendations regarding the prevention and management of periodontitis and these neurological diseases at dental clinics and neurology units.</p></div><div><h3>Development</h3><p>In response to a series of questions proposed by the SEPA-SEN working group, a literature search was performed, with no restrictions on study design, to identify the most relevant articles on the association between periodontitis and cerebrovascular disease and dementia from the perspectives of epidemiology, treatment, and the biological mechanisms involved in these associations.</p></div><div><h3>Conclusions</h3><p>Periodontitis increases the risk of ischaemic stroke and Alzheimer dementia. Recurrent bacterial infections and increased low-grade systemic inflammation seem to be possible biological mechanisms underlying this association. Limited evidence suggests that various oral health interventions can reduce the future risk of cerebrovascular disease and dementia.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 3","pages":"Pages 302-311"},"PeriodicalIF":0.0,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S217358082400018X/pdfft?md5=4bc6a2a6a651232a50edb3134e37f6cb&pid=1-s2.0-S217358082400018X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139473131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sleep disorders in patients with multiple sclerosis in Spain 西班牙多发性硬化症患者的睡眠障碍。

Neurologia

Pub Date : 2024-01-01 DOI: 10.1016/j.nrleng.2021.03.011

G.X. Zhang , W.T. Zhang , S.S. Gao , R.Z. Zhao , W.J. Yu , G. Izquierdo

Objective

This study assesses the presence of sleep disturbances and their relationship with clinical and demographic variables in patients with MS, with a view to establishing correlations between the different variables and the frequency of sleep disturbances.

Methods

The Pittsburgh Sleep Quality Index (PSQI) was used to detect sleep disorders. We contacted patients treated at the MS unit and distributed a questionnaire (PSQI) to 221 patients, receiving 142 usable questionnaires between 8 and 30 September 2019.

Results

The prevalence of patients with sleep disturbances in our study was 74.7% (73.7% in women and 76.8% in men). Therefore, sleep disorders are pervasive in patients with MS, with 3 out of 4 patients experiencing them, a higher rate than that observed in the population without the disease. The frequency of sleep disorders gradually increased in line with age. In the 2 age groups analyzed, 44–54 years and 55–68 years, the proportion of moderate and severe sleep disorders was 42.8% and 53.9%, respectively. Moderate and severe sleep disturbances were observed in 27.5%, 44.7%, and 58.3% of patients with Expanded Disability Status Scale scores of 0–3, 3–6, and >6, respectively.

Conclusion

Our results indicate that sleep disorders are more common in patients with MS than in other populations. Patients with secondary progressive forms of MS more frequently present sleep disturbances, while patients with primary progressive forms report them less frequently. Age and degree of disability were positively correlated with the prevalence and severity of sleep disorders in MS patients.

目的：本研究评估多发性硬化症患者是否存在睡眠障碍及其与临床和人口统计学变量之间的关系：本研究评估多发性硬化症患者是否存在睡眠障碍及其与临床和人口统计学变量之间的关系，以期建立不同变量与睡眠障碍频率之间的相关性：方法：采用匹兹堡睡眠质量指数（PSQI）检测睡眠障碍。我们联系了在多发性硬化症科接受治疗的患者，并向221名患者发放了问卷（PSQI），在2019年9月8日至30日期间共收到142份可用问卷：在我们的研究中，睡眠障碍患者的患病率为74.7%（女性为73.7%，男性为76.8%）。因此，睡眠障碍在多发性硬化症患者中普遍存在，每4名患者中就有3名存在睡眠障碍，这一比例高于未患病人群。睡眠障碍的发生率随着年龄的增长而逐渐增加。在分析的 44-54 岁和 55-68 岁两个年龄组中，中度和重度睡眠障碍的比例分别为 42.8%和 53.9%。在残疾状况扩展量表评分为0-3分、3-6分和大于6分的患者中，分别有27.5%、44.7%和58.3%的患者出现中度和重度睡眠障碍：我们的研究结果表明，与其他人群相比，睡眠障碍在多发性硬化症患者中更为常见。继发性进展型多发性硬化症患者更常出现睡眠障碍，而原发性进展型多发性硬化症患者则较少出现睡眠障碍。年龄和残疾程度与多发性硬化症患者睡眠障碍的发生率和严重程度呈正相关。

{"title":"Sleep disorders in patients with multiple sclerosis in Spain","authors":"G.X. Zhang , W.T. Zhang , S.S. Gao , R.Z. Zhao , W.J. Yu , G. Izquierdo","doi":"10.1016/j.nrleng.2021.03.011","DOIUrl":"10.1016/j.nrleng.2021.03.011","url":null,"abstract":"<div><h3>Objective</h3><p>This study assesses the presence of sleep disturbances and their relationship with clinical and demographic variables in patients with MS, with a view to establishing correlations between the different variables and the frequency of sleep disturbances.</p></div><div><h3>Methods</h3><p>The Pittsburgh Sleep Quality Index (PSQI) was used to detect sleep disorders. We contacted patients treated at the MS unit and distributed a questionnaire (PSQI) to 221 patients, receiving 142 usable questionnaires between 8 and 30 September 2019.</p></div><div><h3>Results</h3><p>The prevalence of patients with sleep disturbances in our study was 74.7% (73.7% in women and 76.8% in men). Therefore, sleep disorders are pervasive in patients with MS, with 3 out of 4 patients experiencing them, a higher rate than that observed in the population without the disease. The frequency of sleep disorders gradually increased in line with age. In the 2 age groups analyzed, 44–54 years and 55–68 years, the proportion of moderate and severe sleep disorders was 42.8% and 53.9%, respectively. Moderate and severe sleep disturbances were observed in 27.5%, 44.7%, and 58.3% of patients with Expanded Disability Status Scale scores of 0–3, 3–6, and >6, respectively.</p></div><div><h3>Conclusion</h3><p>Our results indicate that sleep disorders are more common in patients with MS than in other populations. Patients with secondary progressive forms of MS more frequently present sleep disturbances, while patients with primary progressive forms report them less frequently. Age and degree of disability were positively correlated with the prevalence and severity of sleep disorders in MS patients.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 1","pages":"Pages 29-35"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580823000676/pdfft?md5=d8a44992ddcc91170150fc94066131d1&pid=1-s2.0-S2173580823000676-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139072468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the anticonvulsant and neuroprotective effect of intracerebral administration of growth hormone in rats 评估大鼠脑内注射生长激素的抗惊厥和神经保护作用。

Neurologia

Pub Date : 2024-01-01 DOI: 10.1016/j.nrleng.2023.12.003

I. Zamora-Bello , A. Martínez , L. Beltrán-Parrazal , I. Santiago-Roque , E. Juárez-Aguilar , M.L. López-Meraz

Introduction

The growth hormone (GH) has been reported as a crucial neuronal survival factor in the hippocampus against insults of diverse nature. Status epilepticus (SE) is a prolonged seizure that produces extensive neuronal cell death. The goal of this study was to evaluate the effect of intracerebroventricular administration of GH on seizure severity and SE-induced hippocampal neurodegeneration.

Methodology

Adult male rats were implanted with a guide cannula in the left ventricle and different amounts of GH (70, 120 or 220 ng/3 μl) were microinjected for 5 days; artificial cerebrospinal fluid was used as the vehicle. Seizures were induced by the lithium–pilocarpine model (3 mEq/kg LiCl and 30 mg/kg pilocarpine hydrochloride) one day after the last GH administration. Neuronal injury was assessed by Fluoro-Jade B (F-JB) staining.

Results

Rats injected with 120 ng of GH did not had SE after 30 mg/kg pilocarpine, they required a higher number of pilocarpine injections to develop SE than the rats pretreated with the vehicle, 70 ng or 220 ng GH. Prefrontal and parietal cortex EEG recordings confirmed that latency to generalized seizures and SE was also significantly higher in the 120 ng group when compared with all the experimental groups. FJ-B positive cells were detected in the hippocampus after SE in all rats, and no significant differences in the number of F-JB cells in the CA1 area and the hilus was observed between experimental groups.

Conclusion

Our results indicate that, although GH has an anticonvulsive effect in the lithium–pilocarpine model of SE, it does not exert hippocampal neuroprotection after SE.

简介据报道，生长激素（GH）是海马区神经元抵御不同性质损伤的关键生存因子。癫痫状态（SE）是一种长时间的癫痫发作，会导致大量神经细胞死亡。本研究的目的是评估脑室内注射 GH 对癫痫发作严重程度和 SE 诱导的海马神经变性的影响：成年雄性大鼠左心室植入导管，微量注射不同剂量的GH（70、120或220ng/3μl），持续5天；人工脑脊液作为载体。在最后一次注射 GH 一天后，通过锂-匹洛卡品模型（3mEq/kg 氯化锂和 30mg/kg 盐酸匹洛卡品）诱发癫痫发作。神经元损伤通过荧光玉B（F-JB）染色进行评估：结果：注射120ng GH的大鼠在注射30mg/kg皮洛卡品后没有出现SE，但它们需要比注射载体、70ng或220ng GH的大鼠更多的皮洛卡品注射次数才会出现SE。前额叶和顶叶皮层脑电图记录证实，与所有实验组相比，120ng 组大鼠全身性癫痫发作和 SE 的潜伏期也明显较长。所有大鼠在SE后的海马中都检测到了FJ-B阳性细胞，并且在CA1区和后部的F-JB细胞数量在不同实验组之间没有观察到显著差异：我们的研究结果表明，虽然 GH 在锂-匹罗卡品 SE 模型中具有抗惊厥作用，但它在 SE 后并没有发挥海马神经保护作用。

{"title":"Evaluation of the anticonvulsant and neuroprotective effect of intracerebral administration of growth hormone in rats","authors":"I. Zamora-Bello , A. Martínez , L. Beltrán-Parrazal , I. Santiago-Roque , E. Juárez-Aguilar , M.L. López-Meraz","doi":"10.1016/j.nrleng.2023.12.003","DOIUrl":"10.1016/j.nrleng.2023.12.003","url":null,"abstract":"<div><h3>Introduction</h3><p>The growth hormone (GH) has been reported as a crucial neuronal survival factor in the hippocampus against insults of diverse nature. <em>Status epilepticus</em> (SE) is a prolonged seizure that produces extensive neuronal cell death. The goal of this study was to evaluate the effect of intracerebroventricular administration of GH on seizure severity and SE-induced hippocampal neurodegeneration.</p></div><div><h3>Methodology</h3><p>Adult male rats were implanted with a guide cannula in the left ventricle and different amounts of GH (70, 120 or 220ng/3μl) were microinjected for 5 days; artificial cerebrospinal fluid was used as the vehicle. Seizures were induced by the lithium–pilocarpine model (3mEq/kg LiCl and 30mg/kg pilocarpine hydrochloride) one day after the last GH administration. Neuronal injury was assessed by Fluoro-Jade B (F-JB) staining.</p></div><div><h3>Results</h3><p>Rats injected with 120ng of GH did not had SE after 30mg/kg pilocarpine, they required a higher number of pilocarpine injections to develop SE than the rats pretreated with the vehicle, 70ng or 220ng GH. Prefrontal and parietal cortex EEG recordings confirmed that latency to generalized seizures and SE was also significantly higher in the 120ng group when compared with all the experimental groups. FJ-B positive cells were detected in the hippocampus after SE in all rats, and no significant differences in the number of F-JB cells in the CA1 area and the hilus was observed between experimental groups.</p></div><div><h3>Conclusion</h3><p>Our results indicate that, although GH has an anticonvulsive effect in the lithium–pilocarpine model of SE, it does not exert hippocampal neuroprotection after SE.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 1","pages":"Pages 1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580823000664/pdfft?md5=26b30ec06b8fbfc76e0826096ee06ff1&pid=1-s2.0-S2173580823000664-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139072464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gamification and neurological motor rehabilitation in children and adolescents: a systematic review 游戏化与儿童和青少年的神经运动康复：系统性综述

Neurologia

Pub Date : 2024-01-01 DOI: 10.1016/j.nrleng.2023.12.006

M. Pimentel-Ponce , R.P. Romero-Galisteo , R. Palomo-Carrión , E. Pinero-Pinto , J. Antonio Merchán-Baeza , M. Ruiz-Muñoz , J. Oliver-Pece , M. González-Sánchez

Introduction

Gamification consists of the use of games in non-playful contexts. It is widely employed in the motor rehabilitation of neurological diseases, but mainly in adult patients. The objective of this review was to describe the use of gamification in the rehabilitation of children and adolescents with neuromotor impairment.

Methods

We performed a systematic review of clinical trials published to date on the MEDLINE (PubMed), Scielo, SCOPUS, Dialnet, CINAHL, and PEDro databases, following the PRISMA protocol. The methodological quality of the studies identified was assessed using the PEDro scale.

Results

From a total of 469 studies, 11 clinical trials met the inclusion criteria. We analysed the gamification systems used as part of the rehabilitation treatment of different neuromotor conditions in children and adolescents. Cerebral palsy was the most frequently studied condition (6 studies), followed by developmental coordination disorder (3), neurological gait disorders (1), and neurological impairment of balance and coordination (1).

Conclusion

The use of gamification in rehabilitation is helpful in the conventional treatment of neuromotor disorders in children and adolescents, with increased motivation and therapeutic adherence being the benefits with the greatest consensus among authors. While strength, balance, functional status, and coordination also appear to improve, future research should aim to determine an optimal dosage.

导言游戏化包括在非游戏环境中使用游戏。游戏化广泛应用于神经系统疾病的运动康复，但主要针对成年患者。我们按照PRISMA协议，对MEDLINE（PubMed）、Scielo、SCOPUS、Dialnet、CINAHL和PEDro数据库中迄今为止发表的临床试验进行了系统回顾。结果在总共 469 项研究中，有 11 项临床试验符合纳入标准。我们分析了作为儿童和青少年不同神经运动症状康复治疗一部分的游戏化系统。脑瘫是最常被研究的病症（6 项研究），其次是发育协调障碍（3 项）、神经性步态障碍（1 项）以及神经性平衡和协调障碍（1 项）。虽然力量、平衡、功能状态和协调性似乎也有所改善，但未来的研究应以确定最佳剂量为目标。

{"title":"Gamification and neurological motor rehabilitation in children and adolescents: a systematic review","authors":"M. Pimentel-Ponce , R.P. Romero-Galisteo , R. Palomo-Carrión , E. Pinero-Pinto , J. Antonio Merchán-Baeza , M. Ruiz-Muñoz , J. Oliver-Pece , M. González-Sánchez","doi":"10.1016/j.nrleng.2023.12.006","DOIUrl":"10.1016/j.nrleng.2023.12.006","url":null,"abstract":"<div><h3>Introduction</h3><p>Gamification consists of the use of games in non-playful contexts. It is widely employed in the motor rehabilitation of neurological diseases, but mainly in adult patients. The objective of this review was to describe the use of gamification in the rehabilitation of children and adolescents with neuromotor impairment.</p></div><div><h3>Methods</h3><p>We performed a systematic review of clinical trials published to date on the MEDLINE (PubMed), Scielo, SCOPUS, Dialnet, CINAHL, and PEDro databases, following the PRISMA protocol. The methodological quality of the studies identified was assessed using the PEDro scale.</p></div><div><h3>Results</h3><p>From a total of 469 studies, 11 clinical trials met the inclusion criteria. We analysed the gamification systems used as part of the rehabilitation treatment of different neuromotor conditions in children and adolescents. Cerebral palsy was the most frequently studied condition (6 studies), followed by developmental coordination disorder (3), neurological gait disorders (1), and neurological impairment of balance and coordination (1).</p></div><div><h3>Conclusion</h3><p>The use of gamification in rehabilitation is helpful in the conventional treatment of neuromotor disorders in children and adolescents, with increased motivation and therapeutic adherence being the benefits with the greatest consensus among authors. While strength, balance, functional status, and coordination also appear to improve, future research should aim to determine an optimal dosage.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 1","pages":"Pages 63-83"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580823000718/pdfft?md5=9903a16b87f609e73f3473c953ca5490&pid=1-s2.0-S2173580823000718-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138622264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epileptic and neurodevelopmental encephalopathy associated to SYNGAP1 mutation: Description of a case and treatment response to cannabidiol 与SYNGAP1突变相关的癫痫和神经发育性脑病:一个病例的描述和对大麻二酚的治疗反应。

Neurologia

Pub Date : 2024-01-01 DOI: 10.1016/j.nrleng.2023.12.002

Y. López-Moreno , P. Cabezudo-García , N.L. Ciano-Petersen , G. García-Martín , P.J. Serrano-Castro

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Neurologia

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀